<- Go Home
Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Market Cap
$206.5M
Volume
172.0K
Cash and Equivalents
$15.9M
EBITDA
-$23.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$6.15
52 Week Low
$1.34
Dividend
N/A
Price / Book Value
24.58
Price / Earnings
-7.91
Price / Tangible Book Value
24.58
Enterprise Value
$191.7M
Enterprise Value / EBITDA
-8.12
Operating Income
-$24.1M
Return on Equity
182.55%
Return on Assets
-66.48
Cash and Short Term Investments
$15.9M
Debt
$1.1M
Equity
$8.3M
Revenue
N/A
Unlevered FCF
-$6.6M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium